Interim report 2026
Filed with HKEX · Stock code 3692 · · 89 pages · English
Summary by 6ix AI
The report highlights significant increases in revenue and profit, driven primarily by sales of innovative medicines, which now constitute a major portion of total revenue. Additionally, the company has made notable advancements in its product pipeline, including approvals for several innovative medicines during the reporting period.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Hansoh Pharmaceutical Group Company Limited on 6ix
Earlier from Hansoh Pharmaceutical
- Voluntary announcement - risvutatug rezetecan for injection (HS-20093) for osteosarcoma included in priority review and approval procedure of the nmpa
- Hansoh Pharmaceutical Group: Pharma announces pivotal phase 3 clinical trial of HS-10374 in the treatment of adults with moderate-to-severe plaque psoriasis met the co-primary endpoints
- Voluntary announcement - the phase iii clinical study of HS-10374 in the treatment of moderate-to-severe plaque psoriasis has met the co-primary endpoints
- Voluntary announcement - the clinical trial approval for HS-20197 for injection issued by the national medical products administration
- Hansoh Pharmaceutical Group: Wclc 2026 | hansoh pharma announces proffered oral presentation of phase i study data of HS-10370 combined with adebrelimab and chemotherapy in advanced kras G12C-mutated nsclc
Later from Hansoh Pharmaceutical
- Notification letter to registered shareholders and reply form
- Notification letter to non-registered holders and request form
- Voluntary announcement - biologics license application of risvutatug rezetecan for injection (HS-20093) for osteosarcoma accepted by the nmpa
- Voluntary announcement - update on the marketing authorization status of aumolertinib in the EU
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow Hansoh Pharmaceutical into a list and get an email when it puts out news.
Follow Hansoh Pharmaceutical